Alerta

Optimized RNAi Agents for Inhibiting Expression of Coronavirus (CoV) Viral Genomes, Compositions Thereof, and Methods of Use

Resumen de: US20260022379A1

Described are optimized RNAi agents, compositions that include RNAi agents, and methods for inhibition of coronavirus (CoV) viral genome. The optimized CoV RNAi agents and RNAi agent conjugates disclosed herein inhibit the expression of a SARS-CoV-2 viral genome, and the targeted portions of the genome are conserved across a variety of known coronaviruses. Pharmaceutical compositions that include one or more optimized CoV RNAi agents, optionally with one or more additional therapeutics, are also described. Delivery of the described CoV RNAi agents to pulmonary cells, in vivo, provides for inhibition of CoV viral genome expression, including SARS-CoV-2, which can provide a therapeutic benefit to subjects, including human subjects, for the treatment of various diseases including COVID-19.

ANTI-SARS-COV-1 AND ANTI-SARS-COV-2 ACTIVATABLE RNASE GUIDE SEQUENCES

Resumen de: US20260021204A1

The present disclosure relates to anti-SARS-COV-1 and anti-SARS-COV-2 activatable RNase guide sequences and methods of use for screening, treating, and/or preventing SARS infections and/or COVID-related diseases.

CELL-PERMEANT COVALENT INHIBITORS OF VIRAL CYSTEINE PROTEASES

Resumen de: US20260022111A1

Provided herein are compounds having a structure of formula (I) or formula (II):or a pharmaceutically acceptable salt, solvate, or hydrate thereof, useful in treating or preventing coronavirus infection. In some embodiments, the coronavirus infection is COVID-19 (SARS-COV-19). Also provided are compositions comprising the compounds, as well methods of using the compounds to treat or prevent coronavirus infection.

DRY POWDER INHALATION (DPI) FORMULATION AND PREPARATION METHOD THEREOF

Resumen de: WO2026018060A1

The present invention in general relates to a pharmaceutical formulation, specifically a dry powder inhalation formulation for treatment of Corona virus disease-19 (COVID-19). The formulation comprises of combination of an antiviral and a corticosteroid. The invention further describes the method of preparation of the dry powder inhalation formulation.

VIRUS-LIKE PARTICLES FOR THE TREATMENT OF SARS-COV2

Resumen de: AU2024303786A1

The present disclosure relates to a virus-like particle (VLP) comprising one or more antigens for use as a vaccine. The present disclosure further relates to uses of the vaccine for the treatment of a SARS-CoV-2 infection or coronavirus disease 2019 (COVID-19).

COMPOUNDS AND USES THEREFOR

Resumen de: AU2024308469A1

Disclosed are glycanic compounds and their use for treating or inhibiting the development of a viral infection in a subject, especially a coronavirus infection, such as a SARS-CoV-2 infection, or for treating conditions associated with viral infections, such as an acute inflammatory condition, cytokine release syndrome (CRS) or a cytokine storm, severe acute respiratory syndrome (SARS) or acute respiratory distress syndrome (ARDS).

Bacterial compositions, and uses thereof for treating or preventing an immune mediated disease

Resumen de: WO2026017760A1

5 A composition in oral dosage form comprises tryptophan or at least one tryptophan intermediate, and at least one bacterium that (a) expresses enzymes of the shikimate pathway and is capable of producing tryptophan and/or (b) expresses enzymes of the indole pathway and is capable of producing one or more immunomodulatory metabolites. The composition may include a cohort of bacteria 10 including at least one bacterium that (a) expresses enzymes of the shikimate pathway and is capable of producing tryptophan and at least one bacterium that (b) expresses enzymes of the indole pathway and is capable of producing one or more immunomodulatory metabolites. Typically, the cohort of bacteria is capable of producing the immunomodulatory indole derivatives indole-3-lactic acid (ILA), 15 indole-3-propionic acid (IPA) and indole acrylic acid (IA). The composition finds utility in inhibition or prevention of immune-mediated inflammatory damage in subjects with an immune-mediated infectious or non-infectious disease, and in particular can prevent a severe inflammatory response or incidence of Long Covid in SARS-CoV-19 subjects. 20 (Figure 16)

Compositions and methods for detecting SARS-CoV-2 nucleic acid

Resumen de: AU2025283673A1

Disclosed are nucleic acid oligomers, including amplification oligomers, detection probes, and capture probes, for detection of SARS-CoV-2 nucleic acid. Also disclosed are methods of specific nucleic acid amplification and detection using the disclosed oligomers, as well as corresponding formulations, reaction mixtures, and kits and related methods for preparing aqueous reaction mixtures from dried formulations. ec e c

PEPTIDES WITH ANTIVIRAL ACTIVITY

Resumen de: WO2026019338A1

The invention relates to organic chemistry, pharmacology and medicine and concerns novel antiviral peptides. The claimed peptides are characterized by a high level of antiviral activity and show promise for use in the treatment of infectious diseases caused by a viral infection, inter alia, diseases caused by SARS-CoV-2 such as, for example, a simple infection (such as a fever, a cough and/or a sore throat), pneumonia, acute or severe respiratory infection, hypoxic respiratory failure, acute respiratory distress syndrome, sepsis or septic shock and, in particular, COVID-19.

CELLS FOR TREATMENT AND/OR PREVENTION OF SARS-COV-2 INFECTION AND PRODUCTION METHOD THEREFOR

Resumen de: WO2026018922A1

The purpose of the present disclosure is to provide highly versatile, ready-to-deliver allogenic T cells for novel coronavirus infection, and a production method therefor. The present invention provides: a method for producing a cell population for the treatment and/or prevention of SARS-CoV-2 infection and including T cells or precursor T cells that express a human T cell receptor (TCR) specific to SARS-CoV-2, said method comprising a step for causing the expression of one or more human TCRs specific to SARS-CoV-2 in T cells or precursor T cells in vitro; and a cell population for the treatment and/or prevention of SARS-CoV-2 infection and produced via said method, said cell population comprising allogenically derived T cells or precursor T cells.

USE OF CORONAVIRUS SL5S AS TARGETS IN PREPARATION OF DRUG FOR PREVENTING AND TREATING CORONAVIRUS INFECTION

Resumen de: WO2026016695A1

Disclosed is use of coronavirus SL5s as targets in the preparation of a drug for preventing and treating coronavirus infection. The drug target coronavirus SL5s described in the present invention are the stem-loops 5 of the 5'UTR regions of coronaviruses, which participate in regulating viral mRNA translation. Further disclosed is an inhibitor of the SL5s of 7 human infectious coronaviruses, i.e., an antisense oligonucleotide specifically targeting the SL5s for inhibiting coronavirus infection. Experiments have demonstrated that the application of the antisense oligonucleotide specifically targeting the coronavirus SL5s in vitro can significantly inhibit the translation levels of the coronavirus mRNAs. The coronavirus SL5s described in the present invention can be used as drug targets to screen for candidate drugs for inhibiting coronavirus mRNA translation, showing great significance for the development of anti-coronavirus drugs and the prevention and treatment of coronaviruses in the future.

CORONAVIRUS VACCINE COMPOSITION, METHOD THEREFOR AND USE THEREOF

Resumen de: AU2024280139A1

The present invention relates to an immunogenic composition comprising a recombinant peptide and protein, wherein the recombinant peptide and protein comprise a coronavirus antigen and immunogen, for example, a chimeric antigen and immunogen of an S protein peptide or a fragment, variant or mutant sequence thereof of SARS-CoV-2 Hu-1, SARS-CoV-2 Omicron (BA.5 and/or XBB.1.5) variant, and/or other variants. The immunogenic composition comprises a secreted fusion protein, which comprises a soluble coronavirus antigen, wherein the soluble coronavirus antigen protein is linked, by means of in-frame fusion, to a C-terminal moiety of a collagen capable of self-trimerization to form a disulfide bond-linked trimeric fusion protein. The immunogenic composition can be used for generating an immune response, and can be used in a vaccine composition. Further provided are methods for producing a recombinant peptide and protein, methods for prevention, treatment and/or diagnosis, and a related kit.

PROTEIN AND VACCINE AGAINST INFECTIONS OF SARS-COV-2 OMICRON MUTANT STRAIN XBB AND SUBTYPE THEREOF

Resumen de: EP4682160A1

The present invention relates to a protein and a vaccine against infections by a SARS-CoV-2 Omicron variant XBB and subvariants thereof, which belongs to the medicine field. To address the lack of effective prophylactic and therapeutic agents against the infections caused by SARS-CoV-2 Omicron variant XBB and subvariants thereof, the present invention provides proteins and vaccines against infections by the variants, the vaccines are designed based on the full-length S protein, the receptor-binding domain (RBD) sequence and optimized sequences of SARS-CoV-2 Omicron variant XBB and subvariant XBB.1.5, thereof, which are are capable of aiding the host in combating coronavirus infections, and particularly have a relatively good preventive and therapeutic effect against cross-infections caused by SARS-CoV-2 Omicron variant XBB and subvariants thereof.

SYSTEMS AND METHODS FOR SEQUENCE DESIGN

Resumen de: EP4682890A2

A messenger RNA (mRNA) vaccine has emerged as a promising direction to combat the COVID-19 pandemic. This requires an mRNA sequence that is stable and highly productive in protein expression, features to benefit from greater mRNA secondary structure folding stability and optimal codon usage. Sequence design remains challenging due to the exponentially many synonymous mRNA sequences encoding the same protein. The present disclosure presents embodiments of a linear-time approximation (LinearDesign) reducing the design to an intersection between a Stochastic Context Free Grammar (SCFG) and a Deterministic Finite Automaton (DFA). Embodiments of the LinearDesign may implement an mRNA sequence design using much reduced time with very limited loss. Various methodologies, e.g., finding alternative sequences based on k-best parsing or directly incorporating codon optimality, are presented for incorporating the codon optimality into the design. Embodiments of the LinearDesign may provide efficient computational tools to speed up and improve mRNA vaccine development.

Protective Apparatuses for Minimizing Risk of Transmission of Infection and Associated Systems

Resumen de: AU2025283415A1

Abstract Disclosed herein are protective apparatuses, and associated systems, for minimizing the risk of transmission of SARS-CoV-2 and/or other infectious diseases between individuals in close proximity to one another including, for example, transmission through droplets projecting from the mouth or nasal region of an infected individual. Said apparatuses may comprise a substantially transparent shield component and a handle component comprising a connecting aspect. The protective apparatuses may comprise light emitting diodes of cool or warm white light and associated control means. The protective apparatuses of the present disclosure may further comprise a camera communicatively connected to a display screen. Abstract ec b s t r a c t e c

RECOMBINANT POLYCLONAL PROTEINS TARGETING COVID-19 AND METHODS OF USE THEREOF

Resumen de: US20260015770A1

Provided herein are compositions comprising recombinant polyclonal proteins (RPPs) derived from mammalian plasma cells and plasmablasts. Also provided are methods of using the RPPs.

NEW MERS-COV VACCINE

Resumen de: US20260014245A1

The present invention relates to a mutant receptor-binding domain (MERS-mRBD) of MERS-CoV (middle east respiratory syndrome coronavirus) or a fragment thereof and/or a mutant spike protein (MERS-mSpike) of MERS-CoV or a fragment thereof having a reduced binding strength to the RBD-receptor DPP4 (dipeptidylpeptidase 4) of MERS-CoV compared to the wild type receptor-binding domain of MERS-CoV (MERS-wtRBD) and/or having a reduced binding strength to sialic acid compared to a wild type spike of MERS-CoV (MERS-wtSpike). Furthermore, the present invention relates to and a nucleic acid comprising a nucleotide sequence encoding for the MERS-mRBD or the fragment thereof or the MERS-mSpike or the fragment thereof and a vaccine composition comprising one or more MERS-mRBDs or fragments thereof, one or more MERS-mSpikes, one or more polypeptides or proteins and/or one or more nucleic acids according to the present invention, as well as methods for prevention and/or treatment of diseases caused by MERS-CoV in a subject.

ENVELOPED VIRUS LIKE PARTICLES COMRISING SARS-COV-2 S PROTEIN

Resumen de: US20260014249A1

Provided is an enveloped virus-like particle (eVLP) comprising a substantially full-length recombinant SARS-CoV-2 spike (S) protein. The eVLP may further comprise an additional recombinant SARS-CoV-2 S protein having a different sequence, another recombinant viral antigen, or a recombinant non-viral protein. The eVLP is derived from an animal cell, such as a CHO cell, expressing the recombinant SARS-CoV-2 spike protein. Also provided are methods of producing such eVLPs, compositions including such eVLPs, and methods and uses for the induction of an immune response against a SARS-CoV-2 spike protein and/or prevention of COVID-19 or SARS-CoV-2 infection, employing such eVLPs.

MRNA FOR SARS-COV-2 S PROTEIN AND USE THEREOF

Resumen de: US20260014248A1

The present invention relates to an RNA encoding the S protein of SARS-COV-2, a vaccine comprising the RNA, and uses thereof. The present invention also relates to a universal polynucleotide molecule comprising a 5′-UTR and/or a 3′-UTR, and a nucleic acid sequence encoding a protein and/or polypeptide of interest, and optionally comprising a polyA.

AUTOMATIC, PORTABLE AND MODULAR EXOSKELETON FOR AN UPPER EXTREMITY

Resumen de: WO2026015035A1

The invention relates to a portable exoskeleton for an upper limb, with n DOF (degrees of freedom), for patients recovering physically from COVID-19, having n DOF, wherein said exoskeleton comprises rigid plates on the outside of the arm which are rigid parts arranged in the upper part; joints (elbow, shoulder, clavicle) which connect the rigid plates and allow their movement in all directions in the form of flexion, extension, abduction, adduction, internal and external rotation; guides arranged on top of each of the rigid plates from the back to the forearm; bus cables for information, which pass through the guides starting from the end of the forearm up to the back; supports (straps) located on rigid plates of the exoskeleton, which secure the structure to the body; sensors connected to the information bus cables which terminate in the embedded system which are arranged in the rigid plates of the linkage points or rigid plates suitably located along the entire arm.

REAGENT FOR DETECTING SARS-RELATED CORONAVIRUS

Resumen de: US20260016473A1

The present invention relates to a compound represented by the following general formula (1), or a salt or solvate thereof:in the formula (1), R1, R2, and R3 are as defined in the description.

WHOLE BLOOD ASSAY TO MEASURE RESPONSE TO TYPE I IFNS AND DETECT AUTO-ANTIBODIES NEUTRALIZING IFNS

Resumen de: WO2026015635A1

The present invention provides methods, assays and kits for evaluation and assessment of IP-10 (CXCL10) expression, particularly IFN induction of IP-10, to determine the presence of inborn errors of the Type I IFN or Type II IFN response pathway and/or auto-antibodies directed against, and particularly neutralizing, Type I IFNs or Type II IFNs in a patient. The methods, assays and kits including for assessment and evaluation of individuals prior to vaccination with live attenuated virus vaccines, particularly including yellow fever vaccines and COVID-19 vaccines, to assess risk for vaccine-associated disease and adverse events, and for evaluation, treatment and management of patients, particularly including those who develop vaccine-associated disease. Identification of inborn errors of the Type 1 IFN response pathyway and/or auto-antibodies directed against, and particularly neutralizing, Type I IFNs are associated with severe viral illness, including COVID-19 disease, and vaccine-associated disease, particularly with live attenuated virus vaccines, particularly including yellow fever vaccines, as well as arboviral diseases, including WNV and TSE encephalitis.

COMPOUNDS FOR TREATMENT A CORONAVIRUS INFECTION

Resumen de: US20260015337A1

The present invention is generally directed to inhibitors of SARS-CoV-2-related 3C-like protease (Mpro) useful in the treatment of coronavirus infection and having the Formula (A):

SYNTHESIS METHOD AND APPLICATION OF BENZOTHIASELENAZOLE-1-OXIDE COMPOUND AND DERIVATIVE THEREOF

Resumen de: US20260015332A1

The present invention discloses the synthetic methods and the corresponding applications of a benzothiaselenazole-1-oxide compound and derivatives thereof, in which with sulfoximine and elemental selenium as starting materials, a series of benzothiaselenazole-1-oxide compounds has been synthesized through rhodium-catalyzed direct C—H functionalization reaction. Furthermore, with sulfoximine and elemental selenium as starting materials, a chiral benzothiaselenazole-1-oxide compound is synthesized through direct C—H functionalization reaction by virtue of a chiral phosphoric acid ligand. The present invention can allow specific labeling of sulfydryl structures in polypeptides, carbohydrates, drug molecules, and proteins, as well as in proteins and other biomacromolecules, exhibiting good anti-SARS-CoV-2 activity; and a bioconjugate with trastuzumab according to the present invention can effectively image HER2 receptors on the cell surface and show intense fluorescence, and is applicable to the preparation of an imaging reagent for the HER2 receptors on the cell surface.

SARS-COV-2 VACCINE BOOSTER COMPOSITION

Nº publicación: US20260014247A1 15/01/2026

Solicitante:

SK BIOSCIENCE CO LTD [KR]
SK BIOSCIENCE CO., LTD

Resumen de: US20260014247A1

The present disclosure provides a composition for inducing or maintaining an immune response against SARS-COV-2 virus.